Tag Archives: Raju Prasad
Global Blood Therapeutics (GBT) Receives a Buy from William Blair
William Blair analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) today. The company’s shares closed yesterday at $39.64. Prasad noted: “We note that the company has enrolled another roughly 118 patients with the
William Blair Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)
William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today. The company’s shares closed yesterday at $37.90. Prasad wrote: “We show reported earnings, our estimates, and consensus in exhibit 1.” According to TipRanks.com,
William Blair Maintains Their Buy Rating on Krystal Biotech Inc (KRYS)
William Blair analyst Raju Prasad maintained a Buy rating on Krystal Biotech Inc (KRYS – Research Report) today. The company’s shares opened today at $21.25. According to TipRanks.com, Prasad is a 3-star analyst with an average return of 2.7% and
William Blair Thinks Celyad’s Stock is Going to Recover
William Blair analyst Raju Prasad initiated coverage with a Buy rating on Celyad (NASDAQ: CYAD) today. The company’s shares closed yesterday at $24.45, close to its 52-week low of $22.17. Prasad said: “Celyad S.A. Using the Body’s “Natural Born Killers”
Loxo Oncology (LOXO) Gets a Buy Rating from William Blair
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Loxo Oncology (NASDAQ: LOXO). The company’s shares closed on Friday at $159.60. According to TipRanks.com, Prasad is a 3-star analyst with an average return of
William Blair Maintains a Buy Rating on PTC Therapeutics (PTCT)
William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics (NASDAQ: PTCT) today. The company’s shares opened today at $44.95. Prasad said: “We view this endpoint as particularly impressive given that this milestone is not reached in natural
